Merck-Eisai's Kidney Cancer Drug Combo Fail to Improve Survival in ...

Merck-Eisai's kidney cancer drug combo fail to improve survival in ...

MSD, Eisai report setback in first-line kidney cancer trial

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Apr 21, 2026-

MSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpoints

MSD and Eisai’s combination therapies failed to meet the dual primary endpoints of PFS and OS for RCC in the Phase III LITESPARK-012 trial.The post MSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpoints appeared first on Clinical Trials Arena.

LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.